The efficacy of osteoquin in treating the postmenopausal and senile forms of osteoporosis

A 1-year administration of osteoquine (7-isopropoxyisoflavon) to 20 patients with postmenopausal and senile systemic osteoporosis has shown a pronounced analgetic effect of this drug, its ability to stop the loss of and in some instances to increase bone mass, to stimulate osteogenesis.